◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566) Financial History

Name: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566) operates in the Biotechnology industry and is headquartered in Hangzhou, China with about 1,794 employees. Its market capitalization is roughly CNY 1 billion. In the fiscal year ended 2025-12-31, 2566 reported CNY 1.3B in revenue and CNY 138M in net income.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally.

Interactive charts & full statements →

2566 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	CNY 1.3B	CNY 1.4B	CNY 1.3B	CNY 1.1B	—
Gross Profit	CNY 1.1B	CNY 1.1B	CNY 991M	CNY 854M	—
Operating Income (EBIT)	CNY 160M	CNY 181M	CNY 146M	CNY 61M	—
Net Income	CNY 138M	CNY 139M	CNY 120M	CNY 60M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2566 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Dividends Paid	(CNY 14M)	—	—	(CNY 12M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2566 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 2.1B	CNY 1.9B	CNY 1.3B	CNY 1.2B	—
Total Liabilities	CNY 470M	CNY 405M	CNY 410M	CNY 447M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2566 viewer.

Other Companies in Biotechnology

VOR · Vor Biopharma Inc. — $1 billion
CRVS · Corvus Pharmaceuticals, Inc. — $1 billion
SPTX · Seaport Therapeutics, Inc. — $1 billion
OMER · Omeros Corporation — $1 billion
EYPT · EyePoint, Inc. — $1 billion
DRTS · Alpha Tau Medical Ltd. — $1 billion
SVRA · Savara Inc. — $1 billion
REPL · Replimune Group, Inc. — $1 billion

← 2565 All “0-9” companies 2567 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.